---
title: "浙江佐力药业股份有限公司 (300181.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/300181.SZ.md"
symbol: "300181.SZ"
name: "浙江佐力药业股份有限公司"
industry: "制药"
---

# 浙江佐力药业股份有限公司 (300181.SZ)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.zuoli.com;http://www.jolly.com.cn](www.zuoli.com;http://www.jolly.com.cn) |

## Company Profile

公司成立于 2000 年 1 月，位于风景秀丽的莫干山麓。2011 年 2 月 22 日，公司成功登陆创业板。通过多年的研发、改进，公司实现了珍稀中药材——乌灵参的产业化生产，实现了传统中药材和现代生物技术的结合。公司是一家集科研、生产、销售于一体的国家高新技术现代化制药企业。公司产品包括乌灵系列 (乌灵胶囊、灵泽片、灵莲花颗粒)、百令系列 (百令片、百令胶囊)、中药饮片及中药配方颗粒、聚卡波非钙片等。企业荣誉:2024 年 2 月被评为首批 “浙产中药” 产业品牌，荣获 “西普金奖”，荣获 “全国文明单位”、“国家级绿色工厂”、“浙江省知名商号”、“浙江省重合同、守信用 AAA 级企业”、“...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: B (0.29)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 27 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.51% |  |
| Net Profit YoY | 15.21% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.73 |  |
| Dividend Ratio | 3.57% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 11.64B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.81B |  |


**Multi Score**: B

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 20.86% | A |
| Profit Margin | 21.20% | A |
| Gross Margin | 60.20% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.51% | B |
| Net Profit YoY | 15.21% | B |
| Total Assets YoY | 19.91% | A |
| Net Assets YoY | 20.50% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 471.72% | C |
| OCF YoY | 11.51% | B |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.66 | B |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 31.46% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 浙江佐力药业股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "20.86%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "21.20%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "60.20%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.51%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "15.21%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "19.91%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "20.50%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "471.72%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "11.51%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.66",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "31.46%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 19.51 | 31/222 | 22.65 | 21.30 | 20.10 |
| PB | 3.73 | 159/222 | 4.26 | 3.98 | 3.80 |
| PS (TTM) | 4.14 | 100/222 | 4.71 | 4.38 | 4.21 |
| Dividend Yield | 3.57% | 16/222 | 3.48% | 3.27% | 2.90% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-13T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.06 |
| Highest Target | 23.00 |
| Lowest Target | 23.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/300181.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/300181.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/300181.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
